Evidence map›Paper›PMID 35169795›Full record

ArticlebioRxiv : the preprint server for biology2022

Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice.

Baoling Ying, Suzanne M Scheaffer, Bradley Whitener, Chieh-Yu Liang, Oleksandr Dmytrenko, Samantha Mackin, Kai Wu, Diana Lee, Laura E Avena, Zhenlu Chong and 11 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 41 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Baoling YingDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Suzanne M ScheafferDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Bradley WhitenerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Chieh-Yu LiangDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Oleksandr DmytrenkoDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Samantha MackinDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Kai WuModerna, Inc., Cambridge MA, USA.
Diana LeeModerna, Inc., Cambridge MA, USA.
Laura E AvenaModerna, Inc., Cambridge MA, USA.
Zhenlu ChongDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
James Brett CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
LingZhi MaModerna, Inc., Cambridge MA, USA.
Thu KimModerna, Inc., Cambridge MA, USA.
Caralyn SeinModerna, Inc., Cambridge MA, USA.
Angela WoodsModerna, Inc., Cambridge MA, USA.
Daniela Montes BerruetaModerna, Inc., Cambridge MA, USA.
Andrea CarfiModerna, Inc., Cambridge MA, USA.
Sayda M ElbashirModerna, Inc., Cambridge MA, USA.
Darin K EdwardsModerna, Inc., Cambridge MA, USA.
Larissa B ThackrayDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Moderna Therapeutics (United States) · USWashington University in St. Louis · US

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI157155
6 · The paper itself

Abstract

The B.1.1.529 Omicron variant jeopardizes vaccines designed with early pandemic spike antigens. Here, we evaluated in mice the protective activity of the Moderna mRNA-1273 vaccine against B.1.1.529 before or after boosting with preclinical mRNA-1273 or mRNA-1273.529, an Omicron-matched vaccine. Whereas two doses of mRNA-1273 vaccine induced high levels of serum neutralizing antibodies against historical WA1/2020 strains, levels were lower against B.1.1.529 and associated with infection and inflammation in the lung. A primary vaccination series with mRNA-1273.529 potently neutralized B.1.1.529 but showed limited inhibition of historical or other SARS-CoV-2 variants. However, boosting with mRNA-1273 or mRNA-1273.529 vaccines increased serum neutralizing titers and protection against B.1.1.529 infection. Nonetheless, the levels of inhibitory antibodies were higher, and viral burden and cytokines in the lung were slightly lower in mice given the Omicron-matched mRNA booster. Thus, in mice, boosting with mRNA-1273 or mRNA-1273.529 enhances protection against B.1.1.529 infection with limited differences in efficacy measured.

Identifiers

PMID35169795
PMCPMC8845417
OpenAlexW4211129660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.